Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07123727 · ClinicalTrials.gov registry record · Phase 2
A Study to Examine Anktiva for the Treatment of COVID-19.
A Phase 2 study of Long COVID and Long COVID-19, sponsored by ImmunityBio.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT07123727 is a Phase 2 study of Long COVID and Long COVID-19 that is actively recruiting participants, run by ImmunityBio. The registered enrollment target is 40 participants, below the 2,187-participant average among 50 other Long COVID trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07123727, a Phase 2 study of Long COVID and Long COVID-19, is actively recruiting participants, sponsored by ImmunityBio.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine the safety and effectiveness of Anktiva in treating patients with Long COVID-19 which is defined as persistent symptoms of a COVID-19 infection that remain after the infection is over.
Conditions Studied
Interventions
- DRUG Anktiva
Study Locations (1)
California
- Chan Soon-Schiong Institute for Medicine (CSSIFM) - El Segundo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-09-04 |
| Est. Completion | 2026-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07123727
The ClinicalTrials.gov registry entry for NCT07123727 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,187-participant average among 50 other Long COVID trials with a reported enrollment target (98% lower). The listed sponsor is ImmunityBio, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Long COVID appearing as the primary indexed condition, and to 1 intervention - of which Anktiva is the first listed.
NCT07123727 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07123727 about?
NCT07123727 is a clinical study titled "A Study to Examine Anktiva for the Treatment of COVID-19.". This study will examine the safety and effectiveness of Anktiva in treating patients with Long COVID-19 which is defined as persistent symptoms of a COVID-19 infection that remain after the infection is over.
What is the current status of trial NCT07123727?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-09-04. Estimated completion is 2026-07.
What conditions does trial NCT07123727 study?
This clinical trial studies the following conditions: Long COVID, Long COVID-19, Long COVID Syndrome.
What interventions are being tested in trial NCT07123727?
The interventions under investigation include: Anktiva (DRUG).
Who is sponsoring clinical trial NCT07123727?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07123727 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Long COVID
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NE3107 in Adults With Neurological Symptoms of Long COVID
RECRUITING · Phase 2
-
Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID)
RECRUITING · Phase 2
-
Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation
RECRUITING · Phase 2
-
AT1001 for the Treatment of Long COVID
RECRUITING · Phase 2
-
LIFT: Life Improvement Trial
RECRUITING · Phase 2
-
Antiviral Clinical Trial for Long Covid-19
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.